Eidos Therapeutics Inc $ 128.44 5.91 (4.82%)
Volume:
55,363
Avg Vol (1m):
138,482
Market Cap $:
4.99 Bil
Enterprise Value $:
4.87 Bil
P/E (TTM):
0.00
P/B:
40.35
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.86 | ||
| Equity-to-Asset | 0.76 | ||
| Debt-to-Equity | 0.18 | ||
| Debt-to-EBITDA | -0.22 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 75.24 | ||
| Beneish M-Score | -73.35 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -78625.2 | ||
| Net Margin % | -79392.91 | ||
| ROE % | -64.44 | ||
| ROA % | -53.67 | ||
| ROC (Joel Greenblatt) % | -1905.29 | ||
| 3-Year EBITDA Growth Rate | -103.1 | ||
| 3-Year EPS without NRI Growth Rate | -73 |
EIDX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 40.35 | ||
| PS Ratio | 42813.33 | ||
| EV-to-EBIT | -49.35 | ||
| EV-to-EBITDA | -49.5 | ||
| EV-to-Revenue | 38322.63 | ||
| Current Ratio | 11.1 | ||
| Quick Ratio | 11.1 | ||
| Days Payable | 347.63 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 40.39 | ||
| Earnings Yield (Greenblatt) % | -2.03 |